Thirty Days of Silence Is the Only Yes You Get.
IND strategy under 21 CFR 312 — the application that carries a molecule into human trials, and the living file every later submission stands on.
The IND Is Not a Request. It Is a Notification With Teeth.
Under 21 CFR 312.40, an IND goes into effect 30 days after FDA receives it — unless the agency reaches out first. No approval letter arrives. The design of the system puts the burden on your file: chemistry, manufacturing and controls, pharmacology and toxicology, and a clinical protocol, each strong enough that no reviewer feels compelled to stop you.
That is a higher bar than it sounds. A clinical hold is not a rejection — it is an open-ended stop with your Phase 1 sites staffed and your runway burning. The IND you file is a bet that your weakest section survives a skeptical read, which is why the pre-IND meeting exists and why we rarely skip it.
CMC, nonclinical, and clinical each answer a different question — can you make it, is it safe to try, and is the trial designed to find out.
Three Questions. Three Sections. One Verdict.
An IND is read as three independent arguments that must all hold. The weakest one sets your outcome — not the average.
Pharm / ToxIs It Safe Enough to Try?
GLP toxicology, safety pharmacology, and the starting-dose justification — the studies a hold letter cites when they are thin, and the ones a pre-IND meeting can redesign before you run them.
CMCCan You Actually Make It?
A Phase 1 CMC section sized to the phase — enough control to dose humans, structured to grow into the eventual marketing application rather than be rebuilt for it.
ClinicalWill the Trial Find Out?
The protocol, the investigator brochure, and the monitoring plan — a study designed to detect the harms your nonclinical work predicts, in subjects protected under Part 50.
You File an IND Once. You Maintain It for the Life of the Program.
Everything the program does afterward — every protocol, every new investigator, every safety signal — rides on the original application as an amendment or report.
Day 0 — Submission
The initial IND: CMC, pharm/tox, protocol, investigator brochure — ideally shaped by a pre-IND meeting months earlier.
Day 30 — In effect
Absent FDA contact, dosing may begin. The quietest milestone in drug development, and the one everything upstream serves.
The amendment stream
Protocol amendments, new protocols, information amendments, IND safety reports on 7- and 15-day clocks — the file grows with the program.
Annual reporting
The yearly development report under 312.33 — the discipline that keeps a decade-old IND coherent when the NDA team finally opens it.
The clinical hold is the pathway’s enforcement arm. Under 312.42 FDA can stop a study before it starts or mid-enrollment — and the response is a formal, complete answer to every deficiency, not a phone call. Programs are measured by how rarely they meet one, and by how fast they clear it when they do.
Six Disciplines That Carry an IND.
From the pre-IND meeting to the annual report nobody else wants to own.
Pre-IND Meeting Strategy
The one meeting that can redesign your nonclinical program before you run it — questions framed so FDA’s answers are commitments, not observations.
Chemistry, Manufacturing & Controls
A Phase 1 CMC section sized to the phase — enough control to dose humans, structured to grow into the eventual marketing application.
Nonclinical Program Design
GLP toxicology, safety pharmacology, and the starting-dose justification — the studies a hold letter cites when they are thin.
The Application Build
The IND assembled in eCTD from day one — because this file becomes Module 1 through 5 of your NDA or BLA, and refactoring a paper mess later costs a hire.
Safety Reporting Systems
The 7-day and 15-day IND safety report clocks, aggregate analyses, and the judgment calls on what counts as a suspected, unexpected, serious reaction.
Amendments & Annual Reports
Protocol and information amendments filed cleanly, annual reports under 312.33 — the housekeeping that decides whether year eight runs on records or archaeology.
A well-kept IND is the first draft of the NDA or BLA — the same modules, matured instead of rebuilt.
The Cheapest NDA Is an IND That Was Kept Well.
Programs that treat the IND as a compliance chore pay for it twice: once in clinical holds and amendment churn, and again at filing time, when the NDA or BLA team discovers the CMC story has drifted from what the file says. The IND is the marketing application, ten years early and one-tenth the size.
We run INDs with the end in mind — eCTD structure, a CMC change narrative that stays continuous, and submission operations that make year-eight archaeology unnecessary. Expedited programs — Fast Track, Breakthrough Therapy — ride on the same file, and are easier to win from a clean one.
Six Failure Modes We Are Brought In to Prevent.
Most clinical holds were visible in the file before it was submitted.
The skipped pre-IND meeting
A nonclinical package built on assumptions FDA never blessed — and a hold letter that asks for the study you could have known to run.
A starting dose argued thin
First-in-human dosing justified by tradition instead of a defensible safety margin — the deficiency that stops Phase 1 before subject one.
CMC written for the lab, not the clinic
A manufacturing section that cannot demonstrate control of the material actually going into people — the quiet plurality of clinical holds.
Safety reporting by inbox
SUSAR judgments made ad hoc, 15-day clocks tracked in spreadsheets — until an expedited report goes out late, with the program’s name on it.
Amendment debt
Protocols in the field that no longer match the protocols on file — discovered during a BIMO inspection or, worse, during filing.
The orphaned annual report
312.33 reports skipped in the busy years — leaving the one document that summarizes the program unwritten when partners and reviewers ask for it.
IND Leadership From People Who Have Answered FDA in Writing.
Our pharma leads have taken molecules from pre-IND strategy through effect, holds, and the long maintenance years after.
“An IND has one reader who matters and one deadline that isn’t movable. Write the file so the thirtieth day passes in silence.”
The discipline we bring to first-in-human programs.
Heading Toward First-in-Human? File an IND Built to Go Quiet on Day 30.
Bring senior IND leadership in before the pre-IND meeting — the program you avoid redesigning is your own.
Senior-led. Embedded in your team. No junior hand-offs.